1
|
Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, Oruç Z, Derin S, Turna ZH, Bayram D, Köş FT, Şendur MAN, Sever N, Ercelep Ö, Seyyar M, Kefeli U, Uygun K, Özçelik M, Ön S, Şanlı UA, Canaslan K, Ünek İT, Yücel KB, Özdemir N, Yazıcı O, Güzel HG, Salim DK, Göksu SS, Tatlı AM, Ordu Ç, Selvi O, Sakin A, Büyükbayram ME, Dursun B, Ürün Y, Arak H, Ağdaş G, Uğraklı M, Hendem E, Eryılmaz MK, Bilgin B, Topçu A, Şimşek M, Büyükşimşek M, Akay B, Erdal GŞ, Karataş F, Alan Ö, Çağlayan M, Kahvecioğlu FA, Demirci A, Paksoy N, Çetin B, Gümüş M, Ak N, Aydınalp Y, Paydaş S, Güven DC, Kılıçkap S, Sağlam S. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. Oncologist 2023; 28:875-884. [PMID: 37676712 PMCID: PMC10546829 DOI: 10.1093/oncolo/oyad257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 08/22/2023] [Indexed: 09/08/2023] Open
Abstract
INTRODUCTION This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey. RESULTS The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment. CONCLUSIONS AND RELEVANCE The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
Collapse
Affiliation(s)
- Çağlar Ünal
- Division of Medical Oncology, Department of Internal Medicine, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey
| | - Abdulmunir Azizy
- Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey
| | - Senem Karabulut
- Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey
| | - Didem Taştekin
- Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey
| | - Arif Akyıldız
- Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey
| | - Serkan Yaşar
- Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey
| | - Şuayib Yalçın
- Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey
| | - Eyüp Çoban
- Division of Medical Oncology, Department of Internal Medicine, Uludağ University Hospital, Bursa, Turkey
| | - Türkkan Evrensel
- Division of Medical Oncology, Department of Internal Medicine, Uludağ University Hospital, Bursa, Turkey
| | - Ziya Kalkan
- Division of Medical Oncology, Department of Internal Medicine, Dicle University Hospital, Diyarbakır, Turkey
| | - Zeynep Oruç
- Division of Medical Oncology, Department of Internal Medicine, Dicle University Hospital, Diyarbakır, Turkey
| | - Sümeyra Derin
- Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa University Hospital, İstanbul, Turkey
| | - Zeynep Hande Turna
- Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa University Hospital, İstanbul, Turkey
| | - Doğan Bayram
- Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
| | - Fahriye Tuğba Köş
- Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
| | - Mehmet Ali Nihat Şendur
- Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
| | - Nadiye Sever
- Division of Medical Oncology, Department of Internal Medicine, Marmara University Hospital, İstanbul, Turkey
| | - Özlem Ercelep
- Division of Medical Oncology, Department of Internal Medicine, Marmara University Hospital, İstanbul, Turkey
| | - Mustafa Seyyar
- Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey
| | - Umut Kefeli
- Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey
| | - Kazım Uygun
- Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey
| | - Melike Özçelik
- Division of Medical Oncology, Department of Internal Medicine, Ümraniye Research and Training Hospital, İstanbul, Turkey
| | - Sercan Ön
- Division of Medical Oncology, Department of Internal Medicine, Ege University Hospital, İzmir, Turkey
| | - Ulus Ali Şanlı
- Division of Medical Oncology, Department of Internal Medicine, Ege University Hospital, İzmir, Turkey
| | - Kübra Canaslan
- Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir, Turkey
| | - İlkay Tuba Ünek
- Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir, Turkey
| | - Kadriye Bir Yücel
- Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey
| | - Nuriye Özdemir
- Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey
| | - Ozan Yazıcı
- Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey
| | - Halil Göksel Güzel
- Division of Medical Oncology, Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey
| | - Derya Kıvrak Salim
- Division of Medical Oncology, Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey
| | - Sema Sezgin Göksu
- Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Hospital, Antalya, Turkey
| | - Ali Murat Tatlı
- Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Hospital, Antalya, Turkey
| | - Çetin Ordu
- Division of Medical Oncology, Department of Internal Medicine, Gayrettepe Florence Nightinagle Hospital, İstanbul, Turkey
| | - Oğuzhan Selvi
- Division of Medical Oncology, Department of Internal Medicine, Okmeydanı Research and Training Hospital, İstanbul, Turkey
| | - Abdullah Sakin
- Division of Medical Oncology, Department of Internal Medicine, Bahçelievler Medipol Hospital, İstanbul, Turkey
| | - Mehmet Emin Büyükbayram
- Division of Medical Oncology, Department of Internal Medicine, Ataturk University Hospital, Erzurum, Turkey
| | - Bengü Dursun
- Division of Medical Oncology, Department of Internal Medicine, Ankara University Hospital, Ankara, Turkey
| | - Yüksel Ürün
- Division of Medical Oncology, Department of Internal Medicine, Ankara University Hospital, Ankara, Turkey
| | - Hacı Arak
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep University Hospital, Gaziantep, Turkey
| | - Gözde Ağdaş
- Division of Medical Oncology, Department of Internal Medicine, Osmangazi University Hospital, Eskişehir, Turkey
| | - Muzaffer Uğraklı
- Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey
| | - Engin Hendem
- Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey
| | - Melek Karakurt Eryılmaz
- Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey
| | - Burak Bilgin
- Division of Medical Oncology, Department of Internal Medicine, Konya City Hospital, Konya, Turkey
| | - Atakan Topçu
- Division of Medical Oncology, Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey
| | - Melih Şimşek
- Division of Medical Oncology, Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey
| | - Mahmut Büyükşimşek
- Division of Medical Oncology, Department of Internal Medicine, Adana Research and Training Hospital, Adana, Turkey
| | - Büşra Akay
- Division of Medical Oncology, Department of Internal Medicine, Ankara Yurtaslan City Hospital, Ankara, Turkey
| | - Gülçin Şahingöz Erdal
- Division of Medical Oncology, Department of Internal Medicine, Bakırköy Sadi Konuk Research and Training Hospital, İstanbul, Turkey
| | - Fatih Karataş
- Division of Medical Oncology, Department of Internal Medicine, Karabük University Hospital, Karabük, Turkey
| | - Özkan Alan
- Division of Medical Oncology, Department of Internal Medicine, Koc University Hospital, İstanbul, Turkey
| | - Melek Çağlayan
- Division of Medical Oncology, Department of Internal Medicine, Konya Selçuk University Hospital, Konya, Turkey
| | - Fatma Akdağ Kahvecioğlu
- Division of Medical Oncology, Department of Internal Medicine, Sakarya Research and Training Hospital, Sakarya, Turkey
| | - Ayşe Demirci
- Division of Medical Oncology, Department of Internal Medicine, Sakarya Research and Training Hospital, Sakarya, Turkey
| | - Nail Paksoy
- Division of Medical Oncology, Department of Internal Medicine, Tekirdağ City Hospital, Tekirdağ, Turkey
| | - Bülent Çetin
- Division of Medical Oncology, Department of Internal Medicine, Ondokuz Mayıs University Hospital, Samsun, Turkey
| | - Mahmut Gümüş
- Division of Medical Oncology, Department of Internal Medicine, Göztepe Medeniyet University Hospital, İstanbul, Turkey
| | - Naziye Ak
- Division of Medical Oncology, Department of Internal Medicine, İstanbul Florence Nightinagle Hospital, İstanbul, Turkey
| | - Yasemin Aydınalp
- Division of Medical Oncology, Department of Internal Medicine, Adana Balcalı University Hospital, Adana, Turkey
| | - Semra Paydaş
- Division of Medical Oncology, Department of Internal Medicine, Adana Balcalı University Hospital, Adana, Turkey
| | - Deniz Can Güven
- Division of Medical Oncology, Department of Internal Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey
| | - Saadettin Kılıçkap
- Division of Medical Oncology, Department of Internal Medicine, Ankara Liv Hospital, Ankara, Turkey
| | - Sezer Sağlam
- Division of Medical Oncology, Department of Internal Medicine, Demiroglu Bilim University, İstanbul, Turkey
| |
Collapse
|
2
|
Geneş D, Pekkolay Z, Şimşek M, Saraçoğlu H, Turgut M, Tekeş S, Tuzcu A. COMPARISON OF C-PEPTIDE LEVELS IN MONOGENIC FORMS OF DIABETES WITH OTHER TYPES OF DIABETES: A SINGLE-CENTER STUDY. Acta Endocrinol (Buchar) 2023; 19:281-285. [PMID: 38356972 PMCID: PMC10863950 DOI: 10.4183/aeb.2023.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Abstract
Objective This study aimed to evaluate the utility of C-peptide levels in the differentiation of monogenic forms of diabetes from type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in clinical practice. Subjects and Methods A total of 104 patients aged >16 who visited the Dicle University's Faculty of Medicine between April 2011 and December 2020 and were diagnosed with monogenic diabetes by genetic analysis or with T1DM and T2DM were randomly selected for retrospective evaluation. The C-peptide levels of these patients at the time of diagnosis of diabetes were compared. Results Of the 104 patients, 24 (23%) were diagnosed with maturity-onset diabetes of the young (MODY), 40 (38.5%) with T1DM, and 40 (38.5%) with T2DM. Median C-peptide levels (ng/mL) (interquartile range) were 1.78 (1.24-2.88) in MODY group, 0.86 (0.34-1.22) in T1DM group, and 2.38 (1.58-4.27) in T2DM group. Conclusions There was a difference in C-peptide levels between MODY and T1DM groups but not between MODY and T2DM groups. As per clinical evaluations, although C-peptide levels of patients with MODY are similar to those of patients with T2DM patients, the possibility of C-peptide levels being similar to those required for T1DM diagnosis should also be considered.
Collapse
Affiliation(s)
- D. Geneş
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - Z. Pekkolay
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - M. Şimşek
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - H. Saraçoğlu
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - M. Turgut
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - S. Tekeş
- Medical Biology and Genetics, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - A.K. Tuzcu
- Department of Adult Endocrinology and Metabolism, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| |
Collapse
|
3
|
Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E, Hacıbekiroglu İ, Çakır E, Tanrıkulu E, Çoban E, Ozcelik M, Çelik S, Teker F, Aksoy A, Fırat ST, Tekin Ö, Kalkan Z, Türken O, Oven BB, Dane F, Bilici A, Isıkdogan A, Seker M, Türk HM, Gümüş M. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol 2022; 18:1235-1244. [PMID: 35081732 PMCID: PMC8793921 DOI: 10.2217/fon-2021-1248] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 12/09/2021] [Indexed: 12/13/2022] Open
Abstract
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Ayse Irem Yasin
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Sabin Göktas Aydin
- Medipol University, Department of Medical Oncology, Istanbul 34214, Turkey
| | - Bilge Sümbül
- Bezmialem Vakif University, Department of Microbiology, Istanbul 34093, Turkey
| | - Lokman Koral
- Canakkale 18 March University, Department of Medical Oncology, Canakkale 17020 ,Turkey
| | - Melih Şimşek
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Çağlayan Geredeli
- Okmeydani Training and Research Hospital, Department of Medical Oncology, Istanbul 34384, Turkey
| | - Akın Öztürk
- SureyyapasaChest Dıseases And Thoracıc Surgery Traınıng And Research Hospıtal, Department of Medical Oncology, Istanbul 34844, Turkey
| | - Perihan Perkin
- Yildirim Beyazit University Yenimahalle Training and Research Hospital, Department of Medical Oncology, Ankara 06330, Turkey
| | - Derya Demirtaş
- AnkaraCity Hospital, Department of Medical Oncology, Ankara06800, Turkey
| | - Engin Erdemoglu
- GöztepeMedeniyet University, Department of Medical Oncology, Istanbul 34000, Turkey
| | - İlhan Hacıbekiroglu
- Sakarya University Medicine Faculty, Departmentof Medical Oncology, Sakarya 54050, Turkey
| | - Emre Çakır
- Sakarya University Medicine Faculty, Departmentof Medical Oncology, Sakarya 54050, Turkey
| | - Eda Tanrıkulu
- Haydarpasa Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey
| | - Ezgi Çoban
- Haydarpasa Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey
| | - Melike Ozcelik
- Marmara University School of Medicine, Department of Medical Oncology, Istanbul 34722, Turkey
| | - Sinemis Çelik
- Istanbul Oncology Hospital, Department of Medical Oncology, Istanbul 34846, Turkey
| | - Fatih Teker
- Gaziantep University, Department of Medical Oncology, Gaziantep 27470, Turkey
| | - Asude Aksoy
- Fırat University Faculty of Medicine, Department of Medical Oncology, Elazıg 23119, Turkey
| | - Sedat T Fırat
- Erciyes University, Department of Medical Oncology, Kayseri 38039, Turkey
| | - Ömer Tekin
- InönüUniversity, Department of Medical Oncology, Malatya 44280, Turkey
| | - Ziya Kalkan
- DicleUniversity, Department of Medical Oncology, Diyarbakır 21200, Turkey
| | - Orhan Türken
- MaltepeUniversity, Department of Medical Oncology, Istanbul 34844, Turkey
| | - Bala B Oven
- Bahcesehir University School of Medicine, Department of Medical Oncology, Istanbul 34349, Turkey
| | - Faysal Dane
- Acıbadem University, Department of MedicalOncology, Istanbul 34758, Turkey
| | - Ahmet Bilici
- Medipol University, Department of Medical Oncology, Istanbul 34214, Turkey
| | | | - Mesut Seker
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Hacı M Türk
- Bezmialem Vakif University, Department of Medical Oncology, Istanbul 34093, Turkey
| | - Mahmut Gümüş
- GöztepeMedeniyet University, Department of Medical Oncology, Istanbul 34000, Turkey
| |
Collapse
|
4
|
Abstract
Besides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.
Collapse
Affiliation(s)
- Abdallah TM Shbair
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Ayse Irem Yasin
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Atakan Topçu
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| | - Ganime Coban
- Bezmialem Vakif University, Faculty of Medicine, Department of Pathology, Istanbul, 34093, Turkey
| | - Gokce Deniz Uzunoglu
- Bezmialem Vakif University, Faculty of Medicine, Department of Radiology, Istanbul, 34093, Turkey
| | - Melih Şimşek
- Bezmialem Vakif University, Faculty of Medicine, Department of Medical Oncology, Istanbul, 34093, Turkey
| |
Collapse
|
5
|
Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncol 2021; 17:4545-4559. [PMID: 34431372 DOI: 10.2217/fon-2021-0457] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.
Collapse
Affiliation(s)
- Ali Yılmaz
- Department Of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey
| | - Melih Şimşek
- Department Of Medical Oncology, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey
| | - Zekeriya Hannarici
- Department Of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey
| | - Mehmet E Büyükbayram
- Department Of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey
| | - Mehmet Bilici
- Department Of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey
| | - Salim B Tekin
- Department Of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey
| |
Collapse
|
6
|
Bahçeci A, Paydaş S, Ak N, Ferhatoğlu F, Saip PM, Seydaoğlu G, Bilici M, Şimşek M, Tekin SB, Çalikuşu Z, Yavuz S, Şahin AB, Çubukçu E, Evrensel T, Değirmencioğlu S, Demiray AG, Yumuk PF, Alan Ö, Çikman Dİ, Demirelli FH, Köstek O, Gökyer A, Doğan M, Bal Ö, Çakar B, Gökmen E, Yamaç D, Korkmaz T, Aliyev A, Keskin Ö, Urvay S, Büyükşimşek M, Karadeniz C, Yildiz B, Çinkir HY, Demir H, Beypinar İ, Karaçin C, Eser K, Baykara M, Kiliçkap S, Okutur K, Bulut G, Alkan A, Arpaci E, Pilanci KN, Demir A, Işik D, Yildirim N. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. Cancer Invest 2021; 39:473-481. [PMID: 34014777 DOI: 10.1080/07357907.2021.1933011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
AIM The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. METHOD Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. FINDINGS Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). DISCUSSION The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.
Collapse
Affiliation(s)
- Aykut Bahçeci
- Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| | - Semra Paydaş
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - Naziye Ak
- Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, Turkey
| | - Ferhat Ferhatoğlu
- Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, Turkey
| | - Pınar Mualla Saip
- Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, Turkey
| | - Gülşah Seydaoğlu
- Department of Biostatistics, University of Cukurova, Adana, Turkey
| | - Mehmet Bilici
- Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
| | - Melih Şimşek
- Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
| | - Salim Başol Tekin
- Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
| | - Züleyha Çalikuşu
- Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, Turkey
| | - Sinan Yavuz
- Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, Turkey
| | - Ahmet Bilgehan Şahin
- Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Erdem Çubukçu
- Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Türkkan Evrensel
- Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Serkan Değirmencioğlu
- Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
| | - Atike Gökçen Demiray
- Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
| | - Perran Fulden Yumuk
- Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Özkan Alan
- Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Duygu İlke Çikman
- Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Fuat Hulusi Demirelli
- Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Osman Köstek
- Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Ali Gökyer
- Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Mutlu Doğan
- Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Öznur Bal
- Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Burcu Çakar
- Department of Medical Oncology, Ege University, Izmir, Turkey
| | - Erhan Gökmen
- Department of Medical Oncology, Ege University, Izmir, Turkey
| | - Deniz Yamaç
- Department of Medical Oncology, Ankara Güven Hospital, Ankara, Turkey
| | - Taner Korkmaz
- Acıbadem MAA University School of Medicine, Medical Oncology Division, Acibadem Research Institiute of Senology (Maslak Hospital)
| | - Altay Aliyev
- Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, Turkey
| | - Özge Keskin
- Department of Medical Oncology, Selçuk University, Konya, Turkey
| | - Semiha Urvay
- Department of Medical Oncology, Acibadem Kayseri Hospital, Acibadem MAA University, Kayseri, Turkey
| | - Mahmut Büyükşimşek
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - Cemile Karadeniz
- Department of Medical Oncology, Hatay Antakya State Hospital, Hatay, Turkey
| | - Birol Yildiz
- Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | | | - Hacer Demir
- Department of Medical Oncology, Kayseri Education and Research Hospital
| | - İsmail Beypinar
- Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, Turkey
| | - Cengiz Karaçin
- Department of Medical Oncology, Ankara Diskapi Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Kadir Eser
- Department of Medical Oncology, Mersin University, Mersin, Turkey
| | - Meltem Baykara
- Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
| | - Saadettin Kiliçkap
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Kerem Okutur
- Department of Medical Oncology, Istanbul Memorial Bahcelievler Hospital, Istanbul, Turkey
| | - Gülcan Bulut
- Department of Medical Oncology, Antakya Defne Hospital, Hatay, Turkey
| | - Ali Alkan
- Department of Medical Oncology, Mugla Sıtkı Kocman University, Mugla, Turkey
| | - Erkan Arpaci
- Department of Medical Oncology, Kocaeli Gebze Medicalpark Hospital, Kocaeli, Turkey
| | - Kezban Nur Pilanci
- Department of Medical Oncology, Istanbul Aydın University, Istanbul, Turkey
| | - Atakan Demir
- Department of Medical Oncology, Ankara Güven Hospital, Ankara, Turkey
| | - Deniz Işik
- Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| | - Nilgün Yildirim
- Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| |
Collapse
|
7
|
Şimşek M, Naziro??lu M, Şimşek H, Çay M, Aksakal M, Kumru S. Blood plasma levels of lipoperoxides, glutathione peroxidase, beta carotene, vitamin A and E in women with habitual abortion. Cell Biochem Funct 1998. [DOI: 10.1002/(sici)1099-0844(1998120)16:4<227::aid-cbf787>3.0.co;2-m] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|